ACELYRIN, Inc. (NASDAQ:SLRN) shares are moving higher on Friday after the company announced that it will reveal Phase 2 data for Subcutaneous Lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease.
The Details: ACELYRIN will reveal this data during a virtual investor event on Monday, Jan. 6 at 4:30 PM EST. In addition, the company will unveil the design for the Phase 3 program.
The release of the Phase 3 design comes after a successful End-of-Phase 2 meeting with the Food and Drug Administration.
ACELYRIN CEO Mina Kim, Chief Medical Officer Dr. Shep Mpofu and Chief Commercial Officer Ken Lock will be joined at the virtual event by Drs. Andrea Kossler of the Stanford University School of Medicine and Prem Subramanian of the University of Colorado School of Medicine, both members of ACELYRIN’s Scientific and Patient Advisory Boards.
How To Buy ACELYRIN Stock
By now you're likely curious about how to participate in the market for Acelyrin – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
See Also: Nasdaq Surges Over 1%; Cerence Shares Spike Higher
SLRN Price Action: At the time of writing, ACELYRIN stock is trading 14.6% higher at $3.78, according to data from Benzinga Pro.
Image: Image: Akava Photo from Pixabay
